Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

The t(8;21) RUNX1-ETO translocation is one of the most frequent cytogenetic abnormalities in acute myeloid leukemia (AML). In RUNX1-ETO(+) patient samples, differing classes of activating c-KIT receptor tyrosine kinase mutations have been observed. The most common (12%-48%) involves mutations, such as D816V, which occur in the tyrosine kinase domain, whereas another involves mutations within exon 8 in a region mediating receptor dimerization (2%-13% of cases). To test whether distinct subtypes of activating c-KIT mutations differ in their leukemogenic potential in association with RUNX1-ETO, we used a retroviral transduction/transplantation model to coexpress RUNX1-ETO with either c-Kit(D814V) or c-Kit(T417IΔ418-419) in murine hematopoietic stem/progenitor cells used to reconstitute lethally irradiated mice. Analysis of reconstituted animals showed that RUNX1-ETO;c-Kit(D814V) coexpression resulted in 3 nonoverlapping phenotypes. In 45% of animals, a transplantable AML of relatively short latency and frequent granulocytic sarcoma was noted. Other mice exhibited a rapidly fatal myeloproliferative phenotype (35%) or a lethal, short-latency pre-B-cell leukemia (20%). In contrast, RUNX1-ETO;c-Kit(T417IΔ418-419) coexpression promoted exclusively AML in a fraction (51%) of reconstituted mice. These observations indicate that c-Kit(D814V) promotes a more varied and aggressive leukemic phenotype than c-Kit(T417IΔ418-419), which may be the result of differing potencies of the activating c-Kit alleles.

[1]  Chuanfeng Wu,et al.  C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice , 2011, Proceedings of the National Academy of Sciences.

[2]  F. Bertucci,et al.  Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. , 2010, Blood.

[3]  J. Pollack,et al.  KIT mutations confer a distinct gene expression signature in core binding factor leukaemia , 2010, British journal of haematology.

[4]  Frédéric Subra,et al.  The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment , 2009, Molecular Cancer Research.

[5]  M. Lübbert,et al.  Complementing mutations in core binding factor leukemias: from mouse models to clinical applications , 2008, Oncogene.

[6]  Ming Yan,et al.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. , 2007, Blood.

[7]  Michael H. Tomasson,et al.  Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling , 2006, Molecular and Cellular Biology.

[8]  W. Hiddemann,et al.  Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO , 2006, British journal of haematology.

[9]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Dombret,et al.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.

[11]  F. Ferrara,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2006, Blood.

[12]  I. Kawase,et al.  AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. , 2006, Blood.

[13]  R. Roskoski.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. , 2005, Biochemical and biophysical research communications.

[14]  W. Fiedler,et al.  Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. , 2005, Blood.

[15]  W. Hiddemann,et al.  The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. , 2005, The Journal of clinical investigation.

[16]  H. Mitsuya,et al.  Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) , 2005, Leukemia.

[17]  W. Hiddemann,et al.  KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. , 2005, Blood.

[18]  Guoqiang Chen,et al.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Johan Lennartsson,et al.  Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit , 2005, Stem cells.

[20]  M. Tomasson,et al.  An activated receptor tyrosine kinase, TEL/PDGFβR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Cotta,et al.  Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development. , 2003, Blood.

[22]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[23]  J. Downing.  The core-binding factor leukemias: lessons learned from murine models. , 2003, Current opinion in genetics & development.

[24]  R. Cairoli,et al.  C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index , 2003, Leukemia.

[25]  C. Stocking,et al.  AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency , 2002, The Journal of experimental medicine.

[26]  A. Warren,et al.  Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1-ETO Translocation , 2002, Molecular and Cellular Biology.

[27]  Ana-Teresa Maia,et al.  In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. , 2002, Blood.

[28]  J. Downing,et al.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.

[29]  James R. Downing,et al.  ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain , 2001, Molecular and Cellular Biology.

[30]  I. Weissman,et al.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Tenen,et al.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. , 2000, Blood.

[32]  I. Weissman,et al.  AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[34]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[35]  S. Minucci,et al.  Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO , 1998, Molecular and Cellular Biology.

[36]  C. Glass,et al.  ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors , 1998, Molecular and Cellular Biology.

[37]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Downing,et al.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. , 1998, Blood.

[39]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[40]  M. Marín‐Padilla,et al.  Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene , 1997, Nature Genetics.

[41]  G. Nolan,et al.  Simultaneous fluorescence-activated cell sorter analysis of two distinct transcriptional elements within a single cell using engineered green fluorescent proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Y. Matsuzawa,et al.  Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. , 1996, Blood.

[43]  K. Akashi,et al.  Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. , 1996, Blood.

[44]  M. Marín‐Padilla,et al.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Y. Matsuzawa,et al.  Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase (*) , 1996, The Journal of Biological Chemistry.

[46]  J. Downing,et al.  AML1, the Target of Multiple Chromosomal Translocations in Human Leukemia, Is Essential for Normal Fetal Liver Hematopoiesis , 1996, Cell.

[47]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[48]  H. Drabkin,et al.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. , 1992, Blood.

[49]  M. Ohki,et al.  t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Ohki,et al.  t ( 8 ; 21 ) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene , AMLJ ( chromosomal translocation / cancer genetics , 2022 .